Skip to Content

Inspire Announces Oral Presentation of Phase 2 Epinastine Nasal Spray Data at American College of Allergy, Asthma & Immunology Meeting

DURHAM, N.C.--(BUSINESS WIRE)--Nov 9, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that a presentation of its Phase 2 clinical trial data on epinastine nasal spray for the treatment of allergic rhinitis will be given during the American College of Allergy, Asthma & Immunology (ACAAI) 2007 Annual Meeting on November 8 - 11, 2007 in Dallas. The oral presentation by Paul H. Ratner, M.D., M.B.A., will occur on November 11th at 1:00 p.m. and is based on data contained in the abstract, "Epinastine Nasal Spray is Effective and Well Tolerated for the Treatment of Seasonal Allergic Rhinitis."

The abstract will be available following the conference on Inspire's website,

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are registered trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit


Investor Contact:
Inspire Pharmaceuticals, Inc.
Jenny Kobin, VP, Investor Relations and
Corporate Communications, 919-941-9777, Ext. 219
Media Contact:
BMC Communications
Dan Budwick, 212-477-9007, Ext. 14

Posted: November 2007